Klinische Wochenschrift

, Volume 64, Issue 8, pp 362–365 | Cite as

Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy

  • N. Niederle
  • J. Schütte
  • C. G. Schmidt


Twenty nonseminomatous testicular cancer patients not pretreated with emetogenic chemotherapy were included in a crossover study of antiemetic therapy. Patients were randomly assigned to receive either nabilone (2×2 mg/day) or alizapride (3×150 mg/day) prior to beginning lowdose cisplatin chemotherapy. Patients on nabilone had significantly fewer episodes of emesis than those on alizapride (medians, 1.1 vs 2.9;p<0.01). Nabilone was superior to alizapride in giving complete relief from nausea (medians, 65% vs 30%;p<0.01), and was more effective in shortening the duration of nausea (medians, 1.3 h vs 5.1 h;p<0.01); however, it caused more adverse effects. It is concluded that nabilone has greater antiemetic activity than alizapride in young patients receiving low-dose cisplatin chemotherapy. Nabilone dosage should be reduced to decrease the incidence and degree of adverse reactions while leaving the definite antiemetic activity unchanged.

Key words

Antiemetic therapy Alizapride Cisplatin Nabilone 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Archer AR, Blanchard WB, Day WA, Johnson DW, Lavaganino ER, Ryan CW (1977) Cannabinoids. 3. Synthetic approaches to 9-ketocannabinoids. Total synthesis of nabilone. J Org Chem 42:2277–2284Google Scholar
  2. 2.
    Bleiberg H, Rozencweig M, Nicaise C (1983) Phasc I study of alizapride, a new antiemetic agent. 2nd European Conference on Clinical Oncology and Cancer Nursing, Amsterdam, Abstracts, 219 (19–43)Google Scholar
  3. 3.
    Cheymol G, Mouillé P (1982) Etude des effects cardiovasculaires et anti-arythmisants de l'alizapride. Sem Hop Paris 58:333–338Google Scholar
  4. 4.
    Cupissol D, Favier F, Favier C, Serrou B (1982) Evaluation d'un nouvel anti-emetic l'alizapride, en cancérologie. Sem Hop Paris 58:1370–1373Google Scholar
  5. 5.
    Gralla RJ, Tyson LB, Bordin LA, Clark RA, Kelsen DP, Kris MG, Kalman LB, Groshen S (1984) Antiemetic therapy: A review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. Cancer Treat Rep 68:163–172Google Scholar
  6. 6.
    Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC, Furnas B, Williams SD, Leigh SA, Dorr RT, Moon TE (1979) Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 300:1295–1297Google Scholar
  7. 7.
    Higi M, Niederle N, Bremer K, Schmitt G, Schmidt CG, Seeber S (1982) Levonantradol bei der Behandlung von zytostatikabedingter Übelkeit und Erbrechen. Klinische Erfahrungen. Dtsch med Wochenschr 107:1232–1234Google Scholar
  8. 8.
    Hutcheon AW, Palmer JBD, Soukop M, Cunningham D, McArdle C, Welsh J, Stuart F, Sangster G, Kaye S, Charlton D, Cash H (1985) A randomised multicentre single blind comparison of a cannabinoid anti-emetic (Levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy. Eur J Cancer Clin Oncol 19:1087–1090Google Scholar
  9. 9.
    Johansson R, Kilkku P, Groenroos M (1982) A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treat Rev [Suppl B] 9:25–33Google Scholar
  10. 10.
    Jones SE, Durant JR, Greco FA, Robertone A (1982) A multi-institutional phase III study of nabilone vs. placebo in chemotherapy-induced nausea and vomiting. Cancer Treat Rev [Suppl B] 9:45–48Google Scholar
  11. 11.
    Laville CL, Margarit J (1982) Etude pharmacodynamique de l'alizapride. Sem Hop Paris 58:323–331Google Scholar
  12. 12.
    Lemberger L, Rowe H (1975) Clinical pharmacology of nabilone, a cannabinol derivative. Clin Pharmacol Ther 18:720–726Google Scholar
  13. 13.
    Levitt M (1982) Nabilone vs. placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Cancer Treat Rev [Suppl B] 9:49–53Google Scholar
  14. 14.
    Manegold C, Abel U, Fritze D, Herrmann R (1983) The antiemetic effect of alizapride upon cisplatin-induced emesis. 2nd European Conference on Clinical Oncology and Cancer Nursing, Amsterdam, Abstracts, 216 (19–27)Google Scholar
  15. 15.
    Morrow GR (1984) Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment. J Clin Oncol 2:1170–1176Google Scholar
  16. 16.
    Perrot J, Nahas G, Laville C, Debay A (1981) Substituted benzamides as antiemetics. In: Poster DS, Penta JS, Bruno S (eds) Treatment of cancer chemotherapy-induced nausea and vomiting. Masson Publishing, New York Paris Barcelona Milan Mexico City Rio de Janeior, pp 195–207Google Scholar
  17. 17.
    Preusser P, Achterrath W, Niederle N, Seeber S (1985) Cisplatin. Arzneimitteltherapie 3:50–65Google Scholar
  18. 18.
    Schütte J, Niederle N, Krischke W, Giesche U, Seeber S (1983) Antiemetische Wirksamkeit von Alizaprid bei Cisplatin-bedingtem Erbrechen. Tumordiagnostik & Therapie 4:146–149Google Scholar
  19. 19.
    Steele N, Gralla RJ, Braun DW, Young CW (1980) Doubleblind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep 64:219–224Google Scholar
  20. 20.
    Wada JK, Bogdon DL, Gunnell JC, Hum GJ, Gota CH, Rieth TE (1982) Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy. Cancer Treat Rev [Suppl B] 9:39–44Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • N. Niederle
    • 1
  • J. Schütte
    • 1
  • C. G. Schmidt
    • 1
  1. 1.Innere Universitätsklinik und Poliklinik (Tumorforschung), Westdeutsches TumorzentrumEssen

Personalised recommendations